{"id":124230,"date":"2021-05-07T20:21:57","date_gmt":"2021-05-07T20:21:57","guid":{"rendered":"https:\/\/precoinnews.com\/?p=124230"},"modified":"2021-05-07T20:21:57","modified_gmt":"2021-05-07T20:21:57","slug":"chinas-sinopharm-becomes-first-non-western-vaccine-to-win-who-approval","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/world-news\/chinas-sinopharm-becomes-first-non-western-vaccine-to-win-who-approval\/","title":{"rendered":"China\u2019s Sinopharm becomes first non-Western vaccine to win WHO approval"},"content":{"rendered":"
London:<\/strong> The World Health Organisation has made its long-awaited decision on China\u2019s Sinopharm COVID-19 vaccine, approving the jab for emergency use in all adults, meaning it can be rolled out globally.<\/p>\n The WHO said that based on the available data, the vaccine was 79 per cent effective against symptomatic and hospitalised disease for all ages. Clinical trials run by the state-owned company Sinopharm also showed that it had an efficacy rate of 79 per cent.<\/p>\n <\/p>\n A medical worker poses with a vial of the Sinopharm\u2019s COVID-19 vaccine.<\/span>Credit:<\/span> <\/cite><\/p>\n It will be the first vaccine that will carry vaccine vial monitors – small stickers that will change colour if exposed to heat.<\/p>\n It is also the first time the WHO has given emergency-use approval to a Chinese vaccine for any infectious disease. Earlier this week, separate WHO experts had expressed concern about the quality of data the company provided on side effects.<\/p>\n In its statement approving the vaccine for emergency use, WHO said that as few older adults, aged over 60 were enrolled in trials, the vaccine\u2019s efficacy could not be estimated for this age group.<\/p>\n But it said preliminary data and supportive immunogenicity data suggested the vaccine \u201cis likely to have a protective effect\u201d in older persons.<\/p>\n \u201cThere is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations,\u201d the WHO said.<\/p>\n \u201cWHO therefore recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust.\u201d<\/p>\n The WHO said part of its processes in granting Sinopharm Emergency Use Listing included on-site inspection visits of the Chinese production facilities.<\/p>\nMost Viewed in World<\/h2>\n
From our partners<\/h3>\n